
Figure 1 – Binding ELISA

A.



B.





Figure 2

A


3.5
3
2.5
2
1.5
1
0.5
0
490nm
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
HcLc-1
H17L16
H16L16
H18L16
HcLc-2
H16L18
H6L13

B




3.5
3
2.5
2
1.5
1
0.5
0
490nm
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
HcLc-1
H16L16
H17L16
H18L16
HcLc-2
H16L18
H6L13

Figure 3 – Examples of NOGO binding ELISAs (Supernatant material)

A. Sample set 1



B. Sample set 2





Figure 4 – Examples of NOGO binding ELISAs. Supernatant material

A. Sample set A



B. Sample set B





Figure 5 – Examples of NOGO binding ELISAs. Supernatant material

A. Sample set 1



B. Sample set 2





Figure 6 – Examples of FACS data for humanised anti-NOGO antibodies

A.



B.





Figure 6 C.


mean fluorescence intensity
800
700
600
500
400
300
200
100
0
0.125
0.25
0.5
1
2
4
8
16
32
64
128
antibody concentration µg/ml
HcLc
H1L11
H6Lc
H6L13
11C7

D.




Mean Fuorescence intensity
300
200
100
0
0.5
1
2
4
8
16
32
64
128
Ab concentration µg/ml
HcLc
H1L11
11C7
HcL13
H10L13
H700L11

Figure 6 E.


Mean Fluorescence Intensity
175
150
125
100
75
50
25
0
-ve control
HcLc
H1L11
11C7
H6L13
H10L13
H5L6
H6L6
HcL13
HcL11
H6Lc
H700L11
antibody

F.




Mean Fluorescence intensity
3000
2000
1000
0
0
10
20
30
40
50
antibody concentration (µg/ml)
H16L18
H18L16
H16L16
H17L16
H6L13
H1L11
HcLc
11C7

Figure 7 – Competition ELISA

A.



B.




Figure 8,



2.5
2
1.5
1
0.5
0
OD 490nm
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
H20L16
H22L16
H23L16
H24L16
H1L11
H6L13
H16L16
HcLc

Figure 9,



2.5
2
1.5
1
0.5
0
OD490nm
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
H20L16
H22L16
H23L16
H24L16
H1L11
H6L13
H16L16
HcLc
H20L13
H16L13

Figure 10,



OD490nm
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
H20L16
H22L16
H23L16
H24L16
H1L11
H6L13
H16L16
HcLc
H20L13
H16L13

Figure 11,




2.5
2
1.5
1
0.5
0
OD490nm
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
H20L16
H22L16
H23L16
H24L16
H1L11
H6L13
H16L16
HcLc
H20L13
H16L13

Figure 12,
A


OD490nm
3
2.5
2
1.5
1
0.5
0
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
H19L13
H20L13
H21L13
H23L13
H24L13
HcLc
H6L13
H1L11
H16L16

B



OD490nm
3
2.5
2
1.5
1
0.5
0
0.001
0.01
0.1
1
10
Antibody concentration (mcg/ml)
H19L16
H20L16
H21L16
H22L16
H23L16
H24L16
HcLc
H6L13
H1L11
H16L16

Figure 13,




3000
2000
1000
0
Mean Fluorescence intensity
2
4
8
16
32
64
128
Concentration mcg/ml
2nd Ab only
control Ig
HcLc
H6L13
H1L11
11C7
H16L16
H20L16
H20L13

Figure 14,

A


1200
1100
1000
900
800
700
600
500
400
300
200
100
0
MFI
1
10
100
Ab concentration mcg/ml
HcLc
H20L16
11C7
isotype control

B



650
600
550
500
450
400
350
300
250
200
150
100
50
0
MFI
1
10
100
Concentration mcg/ml
HcLc
H20L16
11C7
isotype control

Figure 14 (continued)

C

